Brown, Emily, Cuthbertson, Daniel J ORCID: 0000-0002-6128-0822 and Wilding, John P ORCID: 0000-0003-2839-8404
(2018)
Newer GLP-1 receptor agonists and obesity-diabetes.
PEPTIDES, 100.
pp. 61-67.
Text
Peptides-Newer GLP-1 receptor agonists and obesity-diabetes-Revision.docx - Author Accepted Manuscript Download (490kB) |
Abstract
Obesity is a major risk factor for type 2 diabetes and may complicate type 1 diabetes. In parallel with the global epidemic of obesity, the incidence of type 2 diabetes is increasing exponentially. To reverse these alarming trends, weight loss becomes a major therapeutic priority in prevention and treatment of type 2 diabetes. Given that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) improve glycaemic control and cause weight loss, they are receiving increasing attention for the treatment of diabetes-obesity. This review discusses current and emerging therapeutic options with GLP-1 RAs and considers the next generation of novel peptide co-agonists with the potential for improved therapeutic outcomes in obesity and type 2 diabetes.
Item Type: | Article |
---|---|
Uncontrolled Keywords: | Diabetes, Obesity, GLP-1 agonists, Review |
Divisions: | Faculty of Health and Life Sciences Faculty of Health and Life Sciences > Institute of Life Courses and Medical Sciences |
Depositing User: | Symplectic Admin |
Date Deposited: | 22 Apr 2021 12:45 |
Last Modified: | 19 Jan 2023 01:14 |
DOI: | 10.1016/j.peptides.2017.12.009 |
Related URLs: | |
URI: | https://livrepository.liverpool.ac.uk/id/eprint/3027553 |